Impacts of Thyroid Eye Disease (TED), Beyond the Signs and Symptoms: Results from the ElevaTED Patient Survey Authors: Jody G. Abrams, Christine Gustafson, Sherry R. Danese, Jennifer Helfer, Shula Pollard, Julie A. Ulloa, Kimberly P. Cockerham Published: 2026 ABSTRACT IntroductionThyroid eye disease (TED) can be visually debilitating and cosmetically disfiguring. Symptoms vary in severity and can lead to drastically impaired quality of life (QoL), ability to work, and mental health. The ElevaTED survey was developed to characterize impacts of TED on QoL, mental health, activities of daily living, sleep, work, and treatment experience.MethodsElevaTED was conducted in July and August 2024. Participants included adult, US residents, with self-reported physician diagnosis of TED and symptoms that negatively impact daily life.ResultsAmong 204 participants who completed the survey, mean age was 50 years (30 to 82) and 74% female. Most (93%) reported experiencing symptoms of TED within the prior month of survey participation, 23% categorized their symptoms as “mild” in severity, 58% “moderate”, and 18% “severe.” Mean number of symptoms experienced was 6 at any time and 3 in the past month, with the most common symptoms reported being “red, swollen, or burning eyes” and “pressure or pain around or behind the eyes.” The majority (72%) of participants indicated their TED symptoms had a “moderate” or “major” impact on their daily life over the prior month. Negative impacts were reported in QoL, sleep, depression, anxiety, and work, across symptom severity groups. Over 80% are worried about their symptoms returning/worsening regardless of treatments and most want to discuss QoL/impacts with their physicians.ConclusionThe results of ElevaTED highlight the impact that TED has on daily activities and mental health and underscore the need for more in-depth physician–patient dialogue beyond the visible signs and symptoms.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40123-026-01393-2. Key Summary Points Why carry out this study?Although the ocular signs and symptoms of thyroid eye disease (TED) are routinely assessed, and prior studies have demonstrated that the clinical symptoms influence patients’ overall quality of life (QoL), mental health, and ability to perform tasks of daily life, more information is needed on the full psychological and functional impact of TED on QoL and daily functioning across different levels of disease severity.This survey was developed to further characterize impacts of TED on QoL, mental health, activities of daily living, sleep, and work as well as understand the current treatment experience for people living with TED.What was learned from this study?The ElevaTED survey found that many people with TED live with depression and anxiety and are limited in their ability to do various activities.Most are very/extremely worried about symptoms returning or worsening and want to discuss more with their physicians regarding QoL and impacts of TED, in addition to their clinical symptoms.Understanding the impact of TED on daily activities, mental health, and other domains not routinely assessed in clinical studies or clinical practice will improve multidisciplinary care and enable more informed treatment decisions. Why carry out this study?Although the ocular signs and symptoms of thyroid eye disease (TED) are routinely assessed, and prior studies have demonstrated that the clinical symptoms influence patients’ overall quality of life (QoL), mental health, and ability to perform tasks of daily life, more information is needed on the full psychological and functional impact of TED on QoL and daily functioning across different levels of disease severity.This survey was developed to further characterize impacts of TED on QoL, mental health, activities of daily living, sleep, and work as well as understand the current treatment experience for people living with TED.What was learned from this study?The ElevaTED survey found that many people with TED live with depression and anxiety and are limited in their ability to do various activities.Most are very/extremely worried about symptoms returning or worsening and want to discuss more with their physicians regarding QoL and impacts of TED, in addition to their clinical symptoms.Understanding the impact of TED on daily activities, mental health, and other domains not routinely assessed in clinical studies or clinical practice will improve multidisciplinary care and enable more informed treatment decisions. Introduction Thyroid eye disease (TED), also known as thyroid-associated ophthalmopathy, Graves’ eye disease (GED), or Graves’ orbitopathy (GO), is an autoimmune and inflammatory condition affecting the orbital tissues. TED is the most prevalent extrathyroidal manifestation of Graves’ disease, presenting in 25–40% [1, 2]. Epidemiology studies conducted in the USA and Europe estimated the prevalence of TED to be 90–300/100,000 population, with an annual incidence rate of approximately 5 per 100,000 person years [1, 3, 4]. Additionally, TED can be visually debilitating and cosmetically disfiguring, with manifestations including retro-orbital inflammation and subsequent exophthalmos, eyelid retraction, swelling of periorbital tissues and conjunctiva, corneal exposure, eye movement/muscle dysfunction (such as strabismus and diplopia), and potentially decreased vision [5]. These symptoms can vary in severity and can lead to drastically impaired quality of life (QoL), decreased ability to work, and diminished mental health [6]. The evaluation and management of TED can be challenging for physicians, as it is a heterogenous condition that presents with a wide range of symptoms and severity and requires coordination of care from ophthalmologists and endocrinologists. In addition to medical and surgical management, recent Clinical Practice Guidelines [7] and joint Medical Association Consensus Statements [5, 8] have highlighted the importance of assessing QoL, impacts to daily living, and psychosocial impacts of TED, even for those with mild disease, to inform treatment decisions. Moreover, regulatory agencies, such as the US Food and Drug Administration, are increasingly emphasizing patient input to identify and validate the most appropriate tools to measure what matters most to patients [9]. To assess QoL in people with TED, various TED-specific questionnaires, instruments, and analytic approaches have been developed [10–15]. Prior studies have clearly demonstrated that the signs and symptoms associated with TED influence patients’ overall QoL, mental health, and ability to perform tasks of daily life. However, the full psychological and functional impact of TED on QoL and daily functioning across different levels of disease severity may not be adequately captured by existing TED-specific instruments [6, 15–21]. Recent advances in patient-reported outcome (PRO) research have sought to address these limitations. Newer studies have explored conceptual frameworks and modern psychometric methods—including item-response theory modeling, digital capture of functional vision measures, and longitudinal evaluation of responsiveness—to improve precision in assessing TED-related burden [15–17]. These investigations collectively underscore the growing recognition that PRO instruments must account for both physical and psychosocial aspects of TED, reflect patient priorities, and be validated for use in clinical trials and real-world settings. Together, these efforts provide the theoretical and empirical foundation for ongoing refinement of TED-specific QoL tools and support the rationale for the current survey study. The purpose of the current study and development of the ElevaTED survey was to build upon the foundation of existing, validated PRO instruments combined with expert input to more fully encompass the perspectives and disease impact of those living with TED of any severity or duration. A better understanding of the impacts of TED on patients’ daily lives and mental health will not only lead to more meaningful patient–physician dialogue but also improve care delivery and better inform the development and evaluation of new treatments. Methods ElevaTED is a cross-sectional, observational, online patient survey that was conducted to characterize the impact of TED on a variety of domains including QoL, mental health, activities of daily living, and work productivity. The ElevaTED survey was developed by Viridian Therapeutics in collaboration with physician experts and a patient advocacy organization, the TED Community Organization. The survey included both novel questions and validated measures to elicit feedback regarding participants’ overall experience living with TED. All questions were multiple choice, and the selection of questions and answer choices came from a review of literature and expert input. ElevaTED survey materials, in English and Spanish, were reviewed, and a waiver was granted by Advarra, an independent review board prior to study initiation, on May 13, 2024, under 45 CFR § 46.104(d). Participation in the survey was voluntary, and all participants provided informed consent for their data to be used anonymously or in aggregate prior to entering the survey. Demographics and nature of TED symptoms were self-reported and collected via survey questions. Symptom severity categories (mild, moderate, severe) were based on patient self-assessment and were intended to capture perceived symptom burden rather than clinical disease staging. Participants were not provided with any predefined criteria or educational materials to guide their individual severity category. The rationale for not providing participants with specific/clinical definitions was that the use of more simplified, subjective PRO measures—such as rating symptoms as “mild,” “moderate,” or “severe”—are increasingly recognized as a powerful way to capture a patient’s personal experience, often providing more meaningful data than strict clinical definitions that may minimize their experience or suffering. These tools are essential for aligning care with patient goals, such as maintaining the ability to function, rather than relying solely on objective measures. In a separate question, participants answered the degree to which their symptoms impacted their daily life to evaluate whether self-reported symptom severity was consistent with self-reported impact to daily life (Supplementary Table S2). Analysis of symptom severity-related outcomes does not include 14 participants who rated their symptom severity as “none/limited.” A variety of validated instruments were used to measure the impact of TED on QoL, sleep, pain, depression, anxiety, health status, and work productivity [11, 22–28]. See the electronic supplementary material for full survey details. The structure of survey questions included multiple-choice questions, rank-order questions (order of importance 1–5), and scale-based responses using a symmetrical 5-point Likert scale of agreement, with presented statements (from “strongly disagree” to “strongly agree”) consistent with established self-reporting survey methodology [29]. The survey was conducted from July 4, 2024 to August 26, 2024. Participants were recruited in collaboration with patient advocacy organizations—Autoimmune Association, Prevent Blindness, Graves’ Disease and Thyroid Foundation, TED Community Organization, and Vision Health Advocacy Coalition—using online recruitment strategies, in addition to a national panel of patients in the USA. All participants were US residents at least 18 years of age in all states except Mississippi (age 21) and Nebraska and Alabama (both age 19). To qualify, participants were required to have a self-reported physician diagnosis of TED with symptoms that had negatively impacted their daily life. On the basis of expert physician input, individuals who self-reported concomitant myasthenia gravis, sarcoidosis, diabetic retinopathy, or uncontrolled glaucoma, as well as uncontrolled hyperthyroidism or hypothyroidism, were excluded from the survey because these conditions may independently affect visual function and QoL, making it difficult to isolate the specific impact of TED. No a priori parameters were used as quotas for recruitment. Participants were eligible if they reported having received a physician diagnosis of TED. A list of inclusion and exclusion criteria for participation is included in Supplementary Table S1. Verification of diagnosis through medical records was not performed because of the anonymous, community-based survey design. All screening and survey details were self-reported, and participants received nominal honorarium for their participation. Participants completed the 30-min survey online via a secure web portal/electronic data capture system. The survey was double-masked and no participant-identifying information was collected or shared with the sponsor. The analysis plan specified continuous variables to be summarized as means, medians, and ranges, and categorical variables as frequency distributions and percentages. As the primary objective of the ElevaTED survey was to characterize patient-reported experiences and generate hypotheses for future research rather than test predefined hypotheses, analyses were intentionally descriptive in nature. Accordingly, the analyses were intended to provide an overview of patient-reported experiences and identify potential areas for further investigation in future hypothesis-driven studies. Results Profile of Respondents The ElevaTED online survey was accessed by 694 adults, of whom 490 were excluded based on defined exclusion criteria, most (46%) due to poorly controlled hyper- or hypothyroidism. An additional 17% were excluded due to poorly controlled glaucoma. An overview of participant screening and exclusion at each stage is provided in Supplementary Fig. S1. Among the 204 participants who qualified and completed the survey, the average age was 50 years (range 30 to 82), 74% were female, and 37 (18%) completed the survey in Spanish. Participants were from 43 US states and included a range of races and ethnicities, similar to general population distributions reported in the USA, with half (53%) being white, 23% of Hispanic, Latino, or Spanish origin, and 21% Black or African American (Table 1). Table 1Profile of ElevaTED survey participantsSelf-reported symptom severity over the past monthTotal*(n = 204)Mild(n = 44)Moderate(n = 111)Severe(n = 35)Moderate/severe combined(n = 146)Mean age, years5049495450Gender Male26%25%29%20%27% Female74%75%71%80%73%Race/ethnicity White53%59%50%51%50% Hispanic, Latino or Spanish origin23%9%27%34%29% Black or African American21%27%19%14%18% Asian3%5%4%–4% American Indian1%–2%–– Prefer to not respond1%1%––Duration of symptoms Months, mean (median)31.9 (16)35.7 (16)24.6 (16)49.5 (18)30.5 (17) Years, mean (median)2.7 (1)3 (1)2 (1)4.1 (2)2.5 (1)Time since diagnosis Months, mean (median)26.7 (15)33.6 (15)21.4 (15)34.2 (16)24.5 (15) Years, mean (median)2.2 (1)2.8 (1)1.8 (1)2.8 (1)2 (1)Area Urban40%57%37%26%34% Suburban42%36%40%54%43% Rural19%7%23%20%23%*14 participants who rated their symptom severity as “none/limited” and therefore were not included in analyses of symptom-severity related outcomes Table 1Profile of ElevaTED survey participantsSelf-reported symptom severity over the past monthTotal*(n = 204)Mild(n = 44)Moderate(n = 111)Severe(n = 35)Moderate/severe combined(n = 146)Mean age, years5049495450Gender Male26%25%29%20%27% Female74%75%71%80%73%Race/ethnicity White53%59%50%51%50% Hispanic, Latino or Spanish origin23%9%27%34%29% Black or African American21%27%19%14%18% Asian3%5%4%–4% American Indian1%–2%–– Prefer to not respond1%1%––Duration of symptoms Months, mean (median)31.9 (16)35.7 (16)24.6 (16)49.5 (18)30.5 (17) Years, mean (median)2.7 (1)3 (1)2 (1)4.1 (2)2.5 (1)Time since diagnosis Months, mean (median)26.7 (15)33.6 (15)21.4 (15)34.2 (16)24.5 (15) Years, mean (median)2.2 (1)2.8 (1)1.8 (1)2.8 (1)2 (1)Area Urban40%57%37%26%34% Suburban42%36%40%54%43% Rural19%7%23%20%23%*14 participants who rated their symptom severity as “none/limited” and therefore were not included in analyses of symptom-severity related outcomes Profile of ElevaTED survey participants *14 participants who rated their symptom severity as “none/limited” and therefore were not included in analyses of symptom-severity related outcomes Symptom Severity Overall, the mean (median) time since participants first experienced TED symptoms was 31.9 (16) months; the mean (median) time since diagnosis was 26.7 (15) months. The vast majority (93%) reported experiencing symptoms of TED within the prior month of survey participation. When asked to describe the severity of their symptoms in the prior month, 23% categorized their symptoms as “mild,” 58% as “moderate,” and 18% as “severe.” Self-reported symptom severity matched self-reported impact on daily life: the majority (80%) of patients reporting mild symptoms reported little impact, the majority (69%) reporting moderate symptoms reported moderate impact, and the majority (80%) reporting severe symptoms reported major impact (Table S2). TED Symptoms and Impact on Daily Life A wide range of TED symptoms were reported. Participants with self-reported moderate or severe symptoms in the prior month had experienced a mean (median) of 3 (2) symptoms in the prior month and 6 (5) symptoms at any time. The most commonly experienced symptoms at any time were “red, swollen or burning eyes” and “pressure or pain around or behind the eyes” (Fig. 1). Results for those reporting mild symptoms (n = 44) are presented in Supplementary Fig. S2. The single most bothersome symptom was most often reported to be “pressure or pain around or behind eyes” and “double vision” among those experiencing the symptom. The majority (72%) of participants indicated their TED symptoms had a “moderate” or “major” impact on their daily life over the prior month.Fig. 1Thyroid eye disease (TED) symptoms experienced by participants at any time or within the prior month for those reporting moderate or severe symptoms (n = 146). See Supplementary Fig. S2 for results for those reporting mild symptoms [*Of Symptoms experienced, 'Pressure of pain around or behind eyes' (68%) and/or 'Double vision' (49%) were ranked as the single most bothersome symptom amongst those experiencing the symptom] Thyroid eye disease (TED) symptoms experienced by participants at any time or within the prior month for those reporting moderate or severe symptoms (n = 146). See Supplementary Fig. S2 for results for those reporting mild symptoms [*Of Symptoms experienced, 'Pressure of pain around or behind eyes' (68%) and/or 'Double vision' (49%) were ranked as the single most bothersome symptom amongst those experiencing the symptom] Impact on Quality of Life Assessment of TED impact on QoL across multiple questionnaires including overall health state (EuroQol-5 Dimension-5 Level [EQ-5D-5L]) and TED-specific QoL (Graves’ Ophthalmopathy Quality of Life [GO-QOL], Thyroid Eye Disease Quality of Life [TED-QOL]) showed consistent results. Participants with self-reported moderate or severe symptoms in the prior month had mean scores well below those for general population for the EQ-5D-5L index and EQ-5D-5L visual analog scale. Notable impairment was also evident on the TED-QOL and GO-QOL overall scale and both subscales, psychosocial effects of a changed appearance and visual functioning (Fig. 2).Fig. 2Mean scores for Thyroid Eye Disease Quality of Life (TED-QOL) (a), Graves’ Ophthalmopathy Quality of Life (GO-QOL) (b), and EuroQol-5 Dimension-5 Level (EQ-5D-5L) (c, d) for those reporting mild (n = 44), moderate (n = 111), or severe symptoms (n = 35) in the prior month Mean scores for Thyroid Eye Disease Quality of Life (TED-QOL) (a), Graves’ Ophthalmopathy Quality of Life (GO-QOL) (b), and EuroQol-5 Dimension-5 Level (EQ-5D-5L) (c, d) for those reporting mild (n = 44), moderate (n = 111), or severe symptoms (n = 35) in the prior month Impact on Activities of Daily Living Specific activities of daily living were assessed using the GO-QOL questionnaire and de novo questions from expert input. The activities that were most frequently affected were the ability to use electronic devices, read, watch television, drive, be outside/do activities outside, and do household chores (Fig. 3).Fig. 3Impact on ability to carry out daily activities based on Graves’ Ophthalmopathy Quality of Life (GO-QOL) and expert input for those reporting mild (n = 44), moderate (n = 111), or severe symptoms (n = 35) in the prior month [*Severe Symptoms n = 32; 3 participants in this group did not have a driver's license] Impact on ability to carry out daily activities based on Graves’ Ophthalmopathy Quality of Life (GO-QOL) and expert input for those reporting mild (n = 44), moderate (n = 111), or severe symptoms (n = 35) in the prior month [*Severe Symptoms n = 32; 3 participants in this group did not have a driver's license] Mental Health Impacts Depression and anxiety, assessed using the validated Patient Health Questionnaire-9 (PHQ-9) and General Anxiety Disorder-7 (GAD-7) questionnaires, were reported by the majority of participants with self-reported moderate or severe symptoms. In the subgroup with mild TED symptoms, depression was uncommon, but anxiety was reported by almost half of participants (Fig. 4a, b). Consistent with this result, almost all participants across all symptom severity subgroups were very/extremely worried about their symptoms returning or getting worse (Fig. 4f).Fig. 4Impact on mental health (a Patient Health Questionnaire-9 (PHQ-9) Depression; b General Anxiety Disorder-7 (GAD-7)), sleep (c overall quality of sleep; d frequency of sleep disturbances), work (e Work Productivity and Activity Impairment Questionnaire: General Health (WPAI-GH) impact of thyroid eye disease (TED) on work, amongst those employed), and worry of symptoms return or worsening (f); for those reporting mild (n = 44, employed n = 32), moderate (n = 111, employed n = 68), or severe symptoms (n = 35, employed n = 14) in the prior month Impact on mental health (a Patient Health Questionnaire-9 (PHQ-9) Depression; b General Anxiety Disorder-7 (GAD-7)), sleep (c overall quality of sleep; d frequency of sleep disturbances), work (e Work Productivity and Activity Impairment Questionnaire: General Health (WPAI-GH) impact of thyroid eye disease (TED) on work, amongst those employed), and worry of symptoms return or worsening (f); for those reporting mild (n = 44, employed n = 32), moderate (n = 111, employed n = 68), or severe symptoms (n = 35, employed n = 14) in the prior month The majority of participants with self-reported moderate or severe symptoms also reported that they avoided intimacy, friends, and professional interactions because of their TED, some “very much so” (intimacy, 30%; friends, 28%; and professional interactions, 21%). Impact on Sleep and Work Productivity About one-third of participants reported an overall sleep quality of less than 5 on a single-question 10-point numeric rating scale and a high frequency of sleep disturbances (score > 11 on the validated Jenkins Sleep Scale). The severity of sleep disturbance appeared to be aligned with the self-reported severity of TED symptoms, with participants with the most severe symptoms having the worst sleep quality (Fig. 4c, d). TED also impacted participants’ productivity at work. The majority of working participants reported a greater than 50% impairment in their productivity and many reported missing work time due to TED, with participants with the most severe symptoms having the greatest difficulty (Fig. 4e). Patient–Physician Interactions The types of physicians the participants saw about their TED included primary care, ophthalmologist, oculoplastic surgeon, endocrinologist, and optometrist. The diagnosing physician was most often an ophthalmologist (73%) for those with self-reported mild symptoms. Participants with self-reported moderate or severe symptoms were more often diagnosed by an oculoplastic surgeon (40%) or an ophthalmologist (44%). At the time of the survey, slightly more than half of participants (58%) were currently under the care of a TED specialist. This was most often an ophthalmologist; however, among participants with self-reported moderate or severe symptoms, the TED specialist was more often an oculoplastic surgeon. Overall, 62% of participants were very or extremely satisfied with the care they were receiving for their TED, but the majority of participants wanted to discuss more with their physicians. In particular, participants wanted to discuss their TED symptoms, eye pain, overall QoL, ability to do daily activities, and sleep quality (Fig. 5).Fig. 5Proportion of participants that selected specific topics they would like to discuss more with their thyroid eye disease (TED) physician for those reporting mild (n = 44), moderate (n = 111), or severe symptoms (n = 35) in the prior month. (n = 204) Proportion of participants that selected specific topics they would like to discuss more with their thyroid eye disease (TED) physician for those reporting mild (n = 44), moderate (n = 111), or severe symptoms (n = 35) in the prior month. (n = 204) Discussion The ElevaTED survey underscores the substantial and multifaceted burden TED places on people across a broad range of symptom durations and severities, reinforcing that TED extends well beyond its visible signs and symptoms. In this community-based survey of 204 participants, less frequently characterized patient-reported impacts of TED were identified. Most respondents indicated they would like to discuss more about their mental health and daily function with their physicians, revealing potential gaps in current patient care. Consistent with results of previous studies [6, 15–21], the findings from ElevaTED reinforce existing knowledge that TED symptoms substantially affect QoL, mental health, and daily activities while also highlighting specific burdens and patient perspectives that may be missed in current clinical practice and research. For example, difficulty using electronic devices emerged as the most frequently impaired daily activity despite not being included in current TED-specific QoL measures. Similarly, sleep disturbances, rarely reported in earlier TED studies but known to worsen QoL and impair daily activities [30, 31], also increased with symptom severity, underscoring the importance of assessing sleep as part of TED management. This survey also highlighted substantial negative effects of TED on participants’ ability to work, an important contributor to the overall economic burden of TED and its treatment. While anxiety and depression have been previously reported in TED, ElevaTED showed clear associations between self-reported severity of TED symptoms and degree of anxiety and depression using general measures (GAD-7 and PHQ-9). Notably, although participants reporting mild symptoms in the prior month described relatively low levels of depression, nearly half (46%) still reported some degree of anxiety, potentially reflecting ongoing concern about symptom recurrence or worsening. In addition, most respondents reported avoiding intimacy, social relationships, and professional interactions to some extent, behaviors that may exacerbate feelings of isolation, depression, and anxiety. Collectively, these findings highlight a potentially underrecognized burden and support integrating psychological assessment as a core component of TED management, potentially with currently available general questionnaires such as GAD-7 and PHQ-9. While generally happy with their physicians, participants expressed a desire for more comprehensive discussions with them that extend beyond clinical symptoms to include QoL, mental health, and the impact of TED on everyday life. Consistent with these observations, Smith and colleagues [2] reported significant limitations in activities of daily living and noted that many individuals with TED perceive that the negative effects of the disease on QoL are insufficiently recognized by their physicians. This perception may be supported by two studies from Wang et al. evaluating TED on QoL from the perspective of endocrinologists and ophthalmologists. These studies found that respondents believed QoL impairment was highly impacted by the activity and severity of TED, mainly driven by clinical features, as opposed to engagement and enjoyment of day-to-day activities and psychological well-being [32, 33]. Community-based reporting offers an accurate reflection of the day-to-day impact of TED, including fluctuations in symptoms, functional limitations, and QoL challenges that may not be fully apparent during episodic clinical encounters. Despite this, several limitations may affect the overall generalizability of the results. As with many patient-reported survey studies, diagnosis and symptom severity were self-reported and could not be independently verified. The cross-sectional design captures patient experiences at a single point in time and does not allow for assessment of disease progression or temporal relationships between disease duration and QoL outcomes. There may have been a recall bias; however, most questions focussed on the participant experience within the prior month. This survey was also subject to sampling bias and may not represent the wider population of people living with TED, as participation was voluntary, required internet access, and was only open to those living in the USA. Additionally, participant recruitment through advocacy organizations may disproportionately represent individuals with higher disease burden or greater engagement in care which may have led to higher rates of reported psychological distress and work impairment than what would be observed across all individuals living with TED. As well, the exclusion of individuals with unstable systemic disease, which was believed necessary to not confound the results, may have resulted in underestimation of TED burden since those with thyroid instability may have more severe TED symptoms and impacts. Attempts were made to reduce bias with the survey being administered in English and Spanish and did include a broad sample of the TED population in the USA, from varied backgrounds and geographic areas, with a range of symptom severities and durations. The demographic profile of respondents with TED in the present survey (mean age 50 years, 74% female) is consistent with that reported in epidemiologic and clinical cohorts, where TED predominantly affects women in midlife and the mean age at diagnosis ranges between 45 and 55 years [34, 35]. The racial and ethnic composition of our sample—53% white, 23% of Hispanic/Latino/Spanish origin, and 21% Black or African American—was broadly representative of US population distributions, indicating that survey participation reflected the demographic diversity of the national TED population. While a limitation of self-reported data is that findings are subjective in nature, they do elucidate the patients’ experience, which is critical to understanding potential gaps in treatment and care for people with TED. Despite these limitations, the survey provides valuable insight into the patient-reported burden of TED and highlights aspects of the disease that may not be fully captured in traditional clinical assessments. While this survey provides important insights into the lived experience and QoL impact of TED, several opportunities remain for future research to build on these findings. Demographic information collected in the current study—specifically age, gender, and ethnic group—was intended to describe the characteristics of the surveyed population rather than to permit comparative analyses between subgroups. Future studies enrolling larger and more diverse samples could explore how PROs differ across demographic strata, enabling more statistically meaningful comparisons. In particular, age-stratified analyses may help clarify how QoL and the impact on daily activities vary between younger and older individuals, whose lifestyles and functional expectations may differ substantially. Likewise, gender-related comparisons could provide further understanding of how social and biological factors contribute to the experience of TED once larger datasets are available. Finally, subsequent publications from this project could extend these findings by examining outcomes according to disease duration, with a specific focus on those living with chronic TED, to better characterize how long-term disease burden influences QoL and psychosocial functioning. Conclusion The results of ElevaTED highlight the impact TED has on daily activities and mental health and underscore the need for more in-depth physician–patient dialogue beyond the visible signs and symptoms. Recognition of the broader range of TED impacts can guide therapeutic decision-making, enhance the development of truly patient-centered research and care pathways, inform the development and evaluation of new therapeutics, and improve overall care for people living with TED. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PDF 741 KB) Supplementary file1 (PDF 741 KB)